Travere Therapeutics Inc (NASDAQ:TVTX)’s traded shares stood at 1.1 million during the last session, with the company’s beta value hitting 0.58. At the close of trading, the stock’s price was $7.67, to imply an increase of 1.32% or $0.1 in intraday trading. The TVTX share’s 52-week high remains $23.17, putting it -202.09% down since that peak but still an impressive 31.55% since price per share fell to its 52-week low of $5.25. The company has a valuation of $583.69M, with an average of 1.15 million shares in intraday trading volume over the past 10 days and average of 1.24 million shares over the past 3 months.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
After registering a 1.32% upside in the last session, Travere Therapeutics Inc (TVTX) has traded red over the past five days. The stock hit a weekly high of 8.41, jumping 1.32% in its intraday price action. The 5-day price performance for the stock is -1.16%, and -7.70% over 30 days. With these gigs, the year-to-date price performance is -14.68%. Short interest in Travere Therapeutics Inc (NASDAQ:TVTX) saw shorts transact 10.26 million shares and set a 8.93 days time to cover.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Looking at statistics comparing Travere Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Travere Therapeutics Inc (TVTX) shares are -10.08% down over the last 6 months, with its year-to-date growth rate higher than industry average at 38.86% against 12.60%. Revenue is forecast to grow 22.80% this quarter before jumping 25.70% for the next one. The rating firms project that company’s revenue will grow 49.00% compared to the previous financial year.
Revenue forecast for the current quarter as set by 13 analysts is $44.37 million. Meanwhile, for the quarter ending Jun 2024, a total of 13 analyst(s) estimate revenue growth to $51.81 million.Earnings reports from the last fiscal year show that sales brought in $56.99 million and $59.7 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -22.10% before dropping -13.20% in the following quarter.
TVTX Dividends
Travere Therapeutics Inc has its next earnings report out between May 02 and May 06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Travere Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
Travere Therapeutics Inc insiders hold 1.01% of total outstanding shares, with institutional holders owning 115.18% of the shares at 116.36% float percentage. In total, 115.18% institutions holds shares in the company, led by Armistice Capital, LLC. As of Jun 29, 2023, the company held over 7.45 million shares (or 9.93% of shares), all amounting to roughly $114.43 million.
The next major institution holding the largest number of shares is Deep Track Capital, Lp with 7.37 million shares, or about 9.83% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $113.2 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Delaware Group Equity Fds V-Small Cap Core Fund as the top two Mutual Funds with the largest holdings of the Travere Therapeutics Inc (TVTX) shares. Going by data provided on Aug 30, 2023, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 4.21 million shares. This is just over 5.61% of the total shares, with a market valuation of $60.05 million. Data from the same date shows that the other fund manager holds a little less at 3.05 million, or 4.06% of the shares, all valued at about 54.51 million.
